Tirzepatide Research: Mechanism, Trial Evidence, and Recent Studies
The short version
Tirzepatide research spans a discovery story (from incretin science to a dual-receptor agonist), a large phase 3 programme in type 2 diabetes (the SURPASS trials) and obesity (the SURMOUNT trials), and a growing set of trials in adjacent conditions — fatty liver disease, sleep apnea, and heart failure. The mechanism is well characterised: a single 39-amino-acid peptide that activates both the GIP and GLP-1 receptors, producing larger glycaemic and weight effects than either receptor alone. The human trial evidence is extensive and of high quality — mostly large, industry-funded randomised controlled trials, which is the standard for a novel prescription drug and worth noting when weighing the evidence. This page organises the evidence base from discovery through recent studies.
Mechanism: how tirzepatide acts on the GIP and GLP-1 receptors
Tirzepatide Tirzepatide research begins with its structural pharmacology. A 2018 discovery paper (Coskun T, et al., Mol Metab; PMID 30473097) characterised LY3298176 as a fatty-acid-modified 39-amino-acid peptide that activated both GIP and GLP-1 receptor signalling in vitro, improved glucose-dependent insulin secretion and glucose tolerance in mice, and produced greater body-weight and food-intake reductions than a selective GLP-1 agonist [1]. Phase 1 data in 142 subjects (healthy volunteers and people with type 2 diabetes) supported once-weekly dosing [1].
A 2020 in vitro characterisation (Willard FS, et al., JCI Insight; PMID 32730231) found tirzepatide is an imbalanced dual agonist — engaging the GIP receptor more fully than the GLP-1 receptor — and exhibits biased GLP-1R signalling that favours cyclic AMP generation over beta-arrestin recruitment (a signalling fork that usually limits receptor sensitivity with prolonged stimulation). In primary islet experiments, beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, proposed as a partial explanation for the enhanced insulin secretion [2].
Cryo-EM structural studies (Zhao F, et al., Nat Commun 2022; PMID 35217653; Sun B, et al., PNAS 2022; PMID 35333651) resolved the near-atomic-level molecular basis for tirzepatide's simultaneous engagement of the GIP and GLP-1 receptors [36][37].
Beyond the pancreas, GIP and GLP-1 receptors are expressed across liver, muscle, adipose tissue, the central nervous system, the heart, the immune system, and the kidneys, enabling the dual receptor engagement to produce cardiometabolic benefits through multiple, partly distinct tissue pathways (Hammoud R, et al., Nat Rev Endocrinol 2023; PMID 36509857) [10]. GIPR agonism specifically contributes to insulin sensitisation by enhancing glucose disposal in white adipose tissue, independent of GLP-1R-driven weight loss, demonstrated in obese GLP-1R-null mice (Samms RJ, et al., J Clin Invest 2021; PMID 34003802) [38].
Tirzepatide vs semaglutide: the head-to-head record
The direct trial comparison of tirzepatide vs semaglutide began with SURPASS-2 (Frias JP, et al., N Engl J Med 2021; n=1879; PMID 34170647), which compared tirzepatide 5/10/15 mg with a selective GLP-1 agonist 1 mg once weekly in adults with type 2 diabetes over 40 weeks [3]. Tirzepatide was non-inferior and superior at all doses for HbA1c reduction (changes of -2.01%, -2.24%, and -2.30% versus -1.86% for the comparator). Body-weight reductions were also greater with tirzepatide (treatment differences -1.9, -3.6, and -5.5 kg) [3].
For obesity without type 2 diabetes, SURMOUNT-5 (2025) provided the first randomised head-to-head in this population, finding -20.2% versus -13.7% mean weight change at 72 weeks in favour of tirzepatide [5] (see tirzepatide weight loss for full detail). A Bucher indirect treatment comparison (Ciudin A, et al., Diabetes Obes Metab 2025; PMID 40537987) using SURMOUNT-2 and STEP 2 found tirzepatide 10 and 15 mg associated with statistically significantly greater weight, BMI, and HbA1c reductions versus the comparator in patients with type 2 diabetes and obesity [39].
Real-world propensity-matched cohort studies (Krüger N, et al., Nat Med 2026; PMID 41207920) found comparable cardiovascular benefit of tirzepatide and the comparator GLP-1 agonist in clinical practice, with both showing numerical reductions versus older comparators [17].
The SURPASS type 2 diabetes programme
The SURPASS trials enrolled more than 10,000 adults with type 2 diabetes across five phase 3 studies. Key findings:
SURPASS-1 (Rosenstock J, et al., Lancet 2021; PMID 34186022): as monotherapy, tirzepatide 5/10/15 mg produced dose-dependent reductions in HbA1c and body weight versus placebo [40]. SURPASS-3 (Ludvik B, et al., Lancet 2021; PMID 34370970): tirzepatide was superior to insulin degludec for HbA1c reduction and weight loss over 52 weeks [41]. SURPASS-6 (Rosenstock J, et al., JAMA 2023; PMID 37786396): tirzepatide was non-inferior and superior to prandial insulin lispro (a short-acting mealtime insulin) added to basal insulin for HbA1c reduction, with 68% versus 36% reaching HbA1c <7.0% and a weight difference of -9.0 kg versus +3.2 kg [42].
Tirzepatide results: post hoc analysis of SURPASS-1 to -5 (Lingvay I, et al., Diabetes Obes Metab 2023; PMID 36514843) found that 43–82% of tirzepatide-treated participants across trials achieved the composite triple endpoint of HbA1c <7.0% + >=5% weight loss + no hypoglycaemia, versus 4–5% with placebo [43].
Beyond glycaemia: MASH, sleep apnea, heart failure
The SYNERGY-NASH trial (Loomba R, et al., N Engl J Med 2024; PMID 38856224; NCT04166773) enrolled adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty liver disease characterised by liver inflammation and fibrosis) and stage 2–3 liver fibrosis. Tirzepatide produced higher rates of MASH resolution without worsening of fibrosis than placebo across all three doses [14]. A post hoc subgroup analysis confirmed consistent effects across MASH stages [44].
SURMOUNT-OSA (Malhotra A, et al., N Engl J Med 2024; PMID 38912654; NCT05412004) enrolled adults with obesity and moderate-to-severe obstructive sleep apnea (graded by apnea-hypopnea index — the number of apnea or hypopnea events per hour of sleep). Tirzepatide 10 or 15 mg over 52 weeks reduced the apnea-hypopnea index by 25.3 events/hour (in participants not using a CPAP breathing device) and 29.3 events/hour (in PAP users) versus approximately 5 events/hour with placebo [15].
SUMMIT (Packer M, et al., N Engl J Med 2025; PMID 39555826; NCT04847557) enrolled patients with heart failure with preserved ejection fraction (HFpEF — a form of heart failure in which the heart's pumping fraction remains normal) and obesity. Tirzepatide improved heart-failure outcomes and reduced events versus placebo [16].
The SURPASS-CVOT cardiovascular outcomes trial (Nicholls SJ, et al., N Engl J Med 2025; PMID 41406444; NCT04255433) compared tirzepatide with an active GLP-1 comparator in adults with type 2 diabetes and established cardiovascular disease [45].